GLP-1RAs (GLP-1 receptor agonists) are a class of drugs that mimic the action of the GLP-1 hormone and work by stimulating the production of insulin, slowing down food digestion and inducing satiety signals in the body
Still, this early study indicates GLP-1 medications therapeutic potential in ocular inflammatory disease
Just how intense the competition was is borne out by the fact in August 1986 another group, based in Copenhagen, separately published a similar finding about GLP-1 to that made by Mojsov and Habeners team (Holst, rskov, Vagn Nielsen, Schwartz)
Much like in the brain, inflammation is a common feature in several ocular pathologies, particularly those relating to the retina
The absence of such behavioral counseling can impede understanding and expectations around medication use and side effects, efficient clinical follow-up, overall efficacy, and long-term weight maintenance
Anti-obesity drug therapy can be offered as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or 2730 kg/m 2 in the presence of at least one weight-related comorbidity, e.g., dysglycemia, hypertension, dyslipidemia, or obstructive sleep apnea